John Hart, Jr.

Distinguished Chair in Neuroscience
Professor - Behavioral and Brain Sciences
Professor of Neurology, Psychiatry, and Clinical Psychology (UTSW)
Medical Science Director of the Center for BrainHealth
Tags: Cognition and Neuroscience

Professional Preparation

M.D.
University of Maryland School of Medicine - 1983
B.A. - Psychology
The Johns Hopkins University - 1979

Research Areas

Research Interests

My research interests have focused on the neural basis of semantic memory in the human brain. My work, spanning several decades, has focused on identifying the organization of semantic memory in the human brain by proposing that there is both a categorical and featural structure to object memory that exists in multiple memory systems in the brain. My laboratory's recent studies have used functional neuroimaging and electrophysiological investigations to explore the neural mechanisms underlying combining these components of an object together to form an integrated object memory. They recently reported that one neural mechanism by which object recall can occur is via synchronizing gamma brain rhythms that are modulated by the thalamus and proposed the Neural Hybrid Model of Semantic Memory. I am now investigating object memory and word finding deficits in multiple disease states in terms of both diagnosing and designing treatment options based on this model.

Publications

Anand, R., Chapman, S., Rackley, A., Keebler, M., Zientz, J., Hart, J. Gist Reasoning Training in Cognitively Normal Seniors. International Journal of Geriatric Psychiatry, in press. ? - Publication
Xu, F., Uh, J., Brier, M., Hart, J., Yezhuvath, U., Gu, H., Yang, Y., Lu, H. The influence of carbon dioxide on brain activity and metabolism in conscious humans. The Journal of Cerebral Blood flow and Metabolism, in press. ? - Publication
Calley, C.S., Buhl, V., Tillman, G.D., Green, T.A., Hart, J. Jr., Haley, R.W., Kraut, M.A. Impaired word finding in ill Gulf War veterans. Brain Imaging and Behavior, in press. ? - Publication
Calley, C., Tillman, G., Womack, K., Moore, P., Hart, J., Jr., Kraut, M. Subjective Report of Word-Finding and Memory Deficits in Normal Aging and Dementia. Cognitive and Behavioral Neurology, in press ? - Publication
Tillman, G., Kimbrell, T., Calley, C., Li, J., Kraut, M., Freeman, T., Hart, J., Jr. Selective Reduction of Combat Threat Memory P300 Response after Right Frontal Lobe rTMS in PTSD. The Journal of Neuropsychiatry and Clinical Neurosciences , in press ? - Publication
Cally, C., Motes, M., Chiang, H., Buhl, V., Spence, J. ,Abdi, H., Anand, R., Maguire, M., Estevez, L., Briggs, R., Freeman, T., Kraut, M., and Hart, J., Jr. (2012). Threat as a Feaure in Visual Semantic Object Memory. Human Brain Mapping, 000:000-000. 2012 - Publication
Brier, M., Ferree, T., Maguire, M., Moore, P., Spence, J., Tillman, G., Hart, J., Kraut, M. Frontal Theta and Alpha Power and Coherence Changes are Modulated by Semantic Complexity in Go/NoGo Tasks. International Journal of Psychophysiology, in press. 2010 - Publication
Tillman GD, Green TA, Ferree TC, Calley CS, Maguire MJ, Briggs R, Hart J Jr, Haley RW, Kraut MA. Impaired response inhibition in ill Gulf War veterans. J. Neurological Sciences, in press. 2010 - Publication
Ferree, T., Brier, M., Hart, J., Kraut, M. Space-time frequency analysis of EEG data using within-subject statistical tests followed by sequential PCA. Neuroimage, 45(1):109-21, 2009. 2009 - Publication
Assaf M, Jagannathan K, Calhoun V, Kraut M, Hart J Jr, Pearlson G. Temporal sequence of hemispheric network activation during semantic processing: a functional network connectivity analysis. Brain and Cognition, 70(2):238-46, 2009. 2009 - Publication

Appointments

Director
University of Texas at Dallas [2006–Present]
Medical Science Director
University of Texas at Dallas [2005–Present]
Professor/ Jane and Bud Smith Distinguished Chair/Cecil Green Chair in Systems Biology
University of Texas at Dallas [2005–Present]

University of Texas at Dallas [2005–Present]
Professor
University of Texas Southwestern Medical Center [2005–Present]
Associate Director
GRECC of CAVHS [2004–2005]
Associate Professor
University of Arkansas for Medical Sciences [2003–2005]
Physician Researcher
GRECC, CAVHS [2002–2005]
Director
Geriatric Memory Disorders Clinic, CAVHS [2002–2005]
Staff Physician
Central Arkansas Veterans Healthcare System [2002–2005]

Projects

Distinct cortical loci for hand vs. footrelated items in an implicit categorization task.
2002–2002 Moo, L., Segal, J., Kraut, M., & Hart, J. Cognitive Neuroscience Society, March, 2002.
Comparison of Neural Activity During Letter and Object Processing.
2002–2002 Kraut, MA., Moo, L.R., Segal, JB., Slotnick, S., & Hart, J ASNR, Vancouver, 2002.
Shifts of cortical substrates subserving word repetition.
2001–2001 Moo, L., Tesoro, MA., Beyderman, L., Breitstein, J, & Hart, J American Academy of Neurology, May, 2001.
lnter- and intra-hemispheric variation in the neural basis of reading.
2000–2000 Moo, L., Tesoro, M, & Hart, J Society For Neuroscience, 2000.
Delayed matching-to-sample performance across the lifespan: Effects on accuracy and latency.
2004–2004 Gardner, E., Chelonis, J, Dornhojfer, J, Henderson, V, Hart, J, Blake, D., Paule, M Association for Behavior Anabzsis, Boston, 2004.

Additional Information

Grant Participation

CURRENT:

  • Principal Investigator, Novel Treatment of Emotional Dysfunction, DOD, CDMRP, W81XWH-09-DMRDP-ARATDA, (year 1 direct costs $750,000, total direct costs $3,000,000, 9/10-8/13).  25% effort.
  • Protocol Co-Chair, HSE Sub-Study: Correlations of Herpes Simplex Virus (HSV) Viral Load with Neuropsychological Outcomes.  NIAID and NINDS (N01-A1-65306, 9/98-8/08; $43,600 yearly direct; $221,419 recent 5 year total direct).   5% effort.
  • Laboratory Director, Berman Laboratory in Learning and Memory, Center for BrainHealth, University of Texas at Dallas, $700,000).  0% effort.
  • Principal Investigator, Human Performance Measures in Humans, Department of Defense (direct costs of project $582,520).  0% effort.
  • Co-PI, Brain and Cognitive Changes after Reasoning or Physical Training in Cognitively Normal Seniors, NIH (year 1 direct costs $379,038, total direct costs $1,000,00, 9/09-8/11).  3% effort.
  • Investigator, Modulation of Brain Activity by Control of the Inspired Air, NIH/NINDS R01 (PI, Lu; Hart PI of UTD subcontract, year 1 UTD direct costs $42,223, total UTD direct costs $225,051, 8/10-7/14).  10% effort.

FORMER:

  • Principal Investigator, Word Retrieval in Gulf War Illness, Veterans Administration (year 1 direct costs $193,180, total costs $285,740; two year project direct costs $381,175, total costs $566,901). 
  • Principal Investigator, Neuropsychiatric Projects, Investigations into Gulf War Illness, Veterans Administration (year 1 direct costs $1,112,318, total costs $2,845,766; two year project direct costs $2,567,897, total costs $3,917,531).
  • Principal Investigator, Neuropsychological and Cognitive Paradigm Sub-Core, Investigations into Gulf War Illness, Veterans Administration (year 1 direct costs $358,101, total costs $508,660; two year project direct costs $718,934, total costs $1,115,593).
  • Principal Investigator, EEG Sub-Core, Investigations into Gulf War Illness, Veterans Administration (year 1 direct costs $608,228, total costs $826, 674; two year project direct costs $954,251, total costs $1,376,257).
  • Co-PI, Emotional Memory Circuits in Gulf War Illness, Veterans Administration (year 1 direct costs $229,547, total costs $354,802; two year project direct costs $442,780; total costs $677,900).
  • Co-PI, Complex Verbal Functions and Basal Ganglia, Veterans Administration (year 1 direct costs $508,407, total costs $773,664; two year project direct costs $987,220, total costs $1,491,168).
  • Protocol Co-Chair, CASG #211 “Investigation of the Natural History of West Nile Virus Infection in Patients with or at Risk for Progression to West Nile Virus Encephalitis and/or Myelitis.”  NIAID and NINDS (N01-A1-65306, 9/98-8/08).
  • Protocol Co-Chair, CASG #210 “A Phase II Randomized Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (Omr-IgG-Am™) Containing High Anti-West Nile Virus Antibody Titers in Patients with, or at Risk for Progression to West Nile Virus (WNV) Encephalitis and/or Myelitis.” NIAID and NINDS (N01-A1-65306, 9/98-8/08).  
  • Co-PI, (PI, Nestler), Center for Advanced ADHD Research, Treatment, and Education, Sparrow Foundation (7/06-6/09).
  • Consultant, (PI, Pearlson), Quantitative Neuroimaging in Psychosis (NIMH, MH43775-14, 3/1/05-2/28/09).
  • Co-PI, (PI, Tao), The Role of Prefrontal Cortex and Amygdala in Self-harming Behavior among Depressed Youth, Grants for Collaborative Research UTSW-UTD (5/07-4/08).
  • Investigator, (PI, Sullivan), Manifestations, causes, and consequences of Protein Energy Undernutrition in elderly TCU residents, Investigator Initiated Research Veterans Administration, (6/05-5/07)
  • Collaborator, (PI, Assaf), Differential Diagnosis of Psychotic Patients Investigates Activation Patterns Related to Semantic Retrieval in Manic Bipolar and Schizophrenia Patients, and its Relationship to Formal Thought Disorder Severity (Donaghue Foundation,  7/1/05-6/30/08).
  • Principal Investigator, Monitoring Electrophysiological Changes in Object Recall in Semantic Memory during Feature Binding.  GlaxoSmithKline, (10/02-9/06).
  • Principal Investigator, Predicting Response to Acetylcholinesterase Inhibitors for New Learning and Semantic Memory in Mild Cognitive Impairment and Alzheimer’s Disease, MIRECC, 5/04-4/06).  
  • Principal Investigator, Assessment of Object Memory in Normal Aging and Mild Cognitive Decline. Biomedical Research Fund, VA. (6/02-5/05).
  • Investigator (PI of Core, Liem), Alzheimer’s Disease Center, Clinical Core, NIH, (AG-00-002, 8/02-7/05).
  • Investigator (PI, Chernoff), Geriatric Mental Health on the Move, Arkansas Geriatric Education Center, HRSA, GEC Grant 1D 31 HP80009.      
  • Investigator (PI, Crone), Electrocorticographhic Correlates of Language, NIH (R01, 5/01-4/06). 
  • Investigator (PI, Corey) Measuring the Hippocampus: A Comparison of Alternative Methods, MIRECC, (7/01-6/02)
  • Principal Investigator, AChE Inhibitor Therapy in the Treatment of Cognitive Deficits Associated with Static Brain Lesions.  Pfizer-Eisai (9/99-9/02).
  • Investigator (PI, van Zijl), Resource Center Grant for the F. M. Kirby Research Center for Functional Brain Imaging, NIH (8/01-7/06).
  • Investigator, Neurobehavioral Research Unit, Kennedy-Krieger Institute.  NICHD.  
  • Investigator, fMRI Correlates of Language Recovery in Children Undergoing Left Hemispherectomy.  Dana Foundation (7/00-6/03). 
  • Investigator, AchE Inhibitor Therapy in the Treatment of Memory Disorders in Patients with Epilepsy.  Pfizer-Eisai (3/01-3/03).
  • Investigator (PI, Hoehn-Saric), Assessment of Citralapam Treatment for GAD with fMRI, Forrest Laboratories. 
  • Principal Investigator, Verbal and Visual Semantic Object Processing Impairments.  K08 DC00099, 4/1/94- 5/31/00. 
  • Investigator, Investigation of Human Cortical Language Maps Using Complementary Functional Localization Techniques: Functional MRI, Cortical Electrical Stimulation, and Electrocorticographic Recordings.  Dana Clinical Hypotheses in Neuroscience Research Program, 1/97-1/00.
  • Investigator, Cognitive and Neuroanatomic Studies of Acquired Dyslexias.  NIH RO1  NS 29973, 12/1/92-11/30/98.
  • Investigator, Metrifonate Investigational Nationwide Trial (MINT).  Bayer Pharmaceutical Division, 12/97-12/98. 
  • Investigator, The Efficacy, Safety, and Tolerability of Lazabemide (Ro 19-6327) vs. Placebo, Administered for One Year in Patients with Probable Alzheimer's Disease (NINCDS/ADRDA Criteria) (PDL 1000P, dated 12/2/96).  Protodigm, 5/97-12/98.
  • Investigator, A 24-Week, Multicenter, Randomized, Double-Blind Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease  (E2020-307, 5/5/97).   Eisai, Inc., 9/97-12/98.
  • Investigator, An Open-label, Six Month Extension of SDZ ENA 713 Studies B351 and B352 to Prospectively Evaluate the Long-term Safety, Tolerability, and Efficacy of 1 through 6 mg b.i.d. (2-12 mg/day) SDZ ENA 713 in Outpatients with Probable Alzheimer's disease, Sandoz Pharmaceuticals Corporation, 1/96-12/97.   
  • Investigator, An Open Label, Multicenter Clinical Trial Evaluating the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Alzheimer's Disease (Protocol #E2020-A001-314), Eisai America, 11/96-12/97.
  • Investigator, A 54-Week, Randomized, Double Blind, Placebo Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) on Functional Outcome in Patients With Alzheimer's Disease With a Staged Crossover to Open Label Donepezil Hydrochloride (E2020) Treatment (Sponsor #E2020-A001-312), Eisai America, 9/96-12/97.
  • Investigator, A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of  Milameline (CI979RU 35926) in Patients With Probable Alzheimer's Disease With Long-Term Open-Label Extension. Protocol 979-15-16, Warner-Lambert Company, 6/96-12/97.
  • Investigator, An Open-label, Multicenter, Extended Evaluation of the Safety and Efficacy of E2020 in  Patients with Alzheimer's Disease. Protocol E2020-A001-303, Eisai America, Inc., 7/94-5/97.
  • Investigator, Clinical Evaluation of the Safety and Efficacy of AF102B vs. Placebo in the Treatment of Patients with Dementia of the Alzheimer's Type, Protocol #94-001FL-105CR, Forrest Laboratories, 1/95-6/96.
  • Investigator, Open-label Extension of Study #94-001FL-1005CR to Evaluate Long-Term Administration of AF102B in the Treatment of Patients with Dementia of the Alzheimer Type, Forest Laboratories, Inc, 1/96-9/96.
  • Investigator, Promoting Recovery after Damage to the Human Brain: What Triggers the Recovery Process.  Seaver Foundation, 7/92-7/96.
  • Investigator, A Prospective, Double-blind, Placebo-controlled, Parallel Group Comparison of the Efficacy and Safety of Two Doses of SDZ 713, 1-4 mg per Day and SDZ ENA 713 6-12 mg per Day in  Patients with  Alzheimer's disease. Sandoz Pharmaceuticals Corporation, 4/95-5/96.
  • Investigator, Charles A. Dana Center for Study of Memory and Aging.  Dana Foundation, 7/92-7/95.
  • Investigator, A 30-week, Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease, Protocol E2020-001-302, Eisai America, 1/94-6/95.
  • Investigator, A Dose-ranging Study of F102B in Patients with Dementia of the Alzheimer's Type (DAT).  Forrest Laboratories.
  • Investigator, Language Organization Studied by Cortical Stimulation.  NINDS 1  R01 NS26553, 4/89-8/95.
  • Investigator, A Trial of 99MTechnetium Bicisate in Healthy Elderly Volunteers and Patients with Mild to Moderate Dementia of the Alzheimer Type,  Protocol 198-017, DuPont Merck Pharmaceutical Company, 2/93-6/94.
  • Investigator, The Neurobiology of Language (extension grant).  McDonnell Foundation-Pew Charitable Trusts, 1/93 - 9/93.
  • Investigator, The Neurobiology of Language.  McDonnell Foundation-Pew Charitable Trusts, 1/90-12/92.
  • Investigator, A Long Term Randomized Placebo Controlled Study of DuP 996 90 and 120 mg Daily in Patients with  Mild to Moderate Dementia of the Alzheimer Type (Long-term study) (U.S.A. Study); Protocol 996-025, DuPont Merck Pharmaceutical Company, 10/91-12/93.
  • Investigator, A Randomized Placebo Controlled Study of DuP 996 90 and 120 mg Daily in Patients with Mild to Moderate Dementia of the Alzheimer Type (U.S.A. Study), Protocol 996-019, DuPont Merck Pharmaceutical Company, 6/91-12/92.
  • Principal Investigator, Object Representation in Language and Sensory Cortices.  McDonnell Foundation-Pew  Charitable Trusts, 7/91-6/92.
  • Investigator, Oxiracetam in the Treatment of Patients with Cognitive Impairment Associated with Dementia of the Alzheimer's Type, SmithKline Beecham, 7/90-1/91.
  • Investigator, Safety and Efficacy of Long-term Use of Oxiracetam in the Treatment of Patients with Cognitive Impairment Associated with Dementia of the Alzheimer's Type, SmithKline Beecham, 10/90-1/91.
  • Investigator,  Dyslexia Studied by Direct Electrical Cortical Interference in Humans.  Seaver Foundation, 7/89-12/91.
  • Investigator, Controlled Pilot Trial of Dextromethorphan as Adjunct Therapy for Complex Partial Seizures, Nova Pharmaceuticals.
Personal Statement

Dr. Hart's research interests have focused on the neural basis of semantic memory in the human brain. His work spanning several decades has focused on identifying the organization of semantic memory in the human brain by proposing that there is both a categorical and featural structure to object memory that exists in multiple memory systems in the brain. His laboratory's recent studies have used functional neuroimaging and electrophysiological investigations to explore the neural mechanisms underlying combining these components of an object together to form an integrated object memory. They recently reported that one neural mechanism by which retrieval of this object memory can occur is via synchronizing gamma brain rhythms that are modulated by the thalamus. This mechanism of stored knowledge via the thalamus is modulated by the pre-SMA and caudate to facilitate effective retrieval. These findings have led to his group's proposal of the Neural Hybrid Model of Semantic Memory to account for how the brain stores and retrieves object memory. He is now investigating object memory and word finding deficits in multiple disease states in terms of both diagnosing and designing treatment options based on this model.

Committees
  • 2006- Protocol Review and Monitoring Committee, Advanced Imaging Research Center, University of Texas
  • 1997-2001 Functional Imaging Committee (The Johns Hopkins University)
  • 1998 Coding and Reimbursement Subcommittee ofthe Scope of Practice Committee (American Academy of Neurology)
  • 1998-2001 Cingulotomy/Psychosurgeiy Review Committee (The Johns Hopkins Hospital)
  • 1998-2001 Committee on Appointments and Promotions (Neurology Department, The Johns Hopkins University School of Medicine)
  • 1999-2001 Chairman, Practice Issues Committee, Behavioral Neurology Section, American Academy of Neurology
  • 1999-2001 Co-Chair, Residency Selection Committee (Neurology Department, The Johns Hopkins University School of Medicine)
  • 2000-2002 Secretary/Treasurer Behavioral Neurology Section of the American Academy of Neurology
  • 2000-2002 Secretary/Treasurer Society for Behavioral and Cognitive Neuroscience
  • 2001 -2004 Chairman, Subspeciality Certification Committee, Behavioral Neurology Section, American Academy of Neurology
  • 2002-2005 President-elect Behavioral Neurology Section of the American Academy of Neurology
  • 2002-2005 President-elect Society for Behavioral and Cognitive Neuroscience
  • 2002 Co-Chairman, Faculty Retreat, Dept. of Geriatrics, UAMS
  • 2002-2005 Co-Chairman, Linkages Committee, Dept. of Geriatrics, UAMS
  • 2004-2005 Adult Day Healthcare Advisory Program Committee, CAVHS
  • 2004-2005 Telehome Care lmplementation Team, CAVHS
  • 2004-2005 V1SN 16, Care Coordination and Telehealth
  • 2005 AAN representative and original sponsor of Functional Brain Mapping billing code approved by AMA CPT Committee
  • 2006 AAN Representative to the RUC for approval and establishment of relative value units to for Functional Brain Mapping (2/2-5/06)
  • 1999- Executive Committee, Behavioral Neurology Section, American Academy of Neurology
  • 2000- Medical Economics and Management Committee, American Academy of Neurology, Behavioral Neurology Representative
  • 2002- Membership Committee, Academy of Aphasia
  • 2005- President Behavioral Neurology Section of the American Academy of Neurology
  • 2005- President Society for Behavioral and Cognitive Neuroscience

News Articles

Neuroscientists Use Magnetic Stimulation to Amplify PTSD Therapy
Researchers from The University of Texas at Dallas have found that a standard therapy for post-traumatic stress disorder (PTSD) is more effective when paired with transcranial magnetic stimulation of the brain.

Dr. John Hart Jr., Dr. Michael Motes and a team of researchers examined whether the effectiveness of cognitive processing therapy (CPT) in treating PTSD could be boosted by adding repetitive transcranial magnetic stimulation (rTMS) just prior to the CPT sessions.
Study Finds Cognitive Impairment in Some Retired NFL Players
A study led by the UT Dallas Center for BrainHealth examining the neuropsychological status of former National Football League players has found heightened incidence of cognitive deficits and depression among retired players.

But researchers from the center and from UT Southwestern Medical Center say their study, published online Monday in JAMA Neurology, also is significant for what it did not find: evidence of cognitive impairment in the majority of ex-players.
New BrainHealth Test May Detect Who Is Most at Risk for Alzheimer's

Researchers at Center for BrainHealth at UT Dallas have developed a test that may help detect who is at risk for Alzheimer’s disease. 


In a study published in the Journal ofAlzheimer’s Disease, scientists found that individuals with amnestic mild cognitive impairment (aMCI) have twice the risk of others in their age group of progressing to Alzheimer’s after identifying a specific variation in their brain waves. 

PTSD Researchers Win Nearly $7.4M Department of Defense Grant
A University of Texas at Dallas neuroscience research team led by Dr. John Hart Jr. has received a nearly $7.4 million grant from the U.S. Department of Defense for a multisite study on a novel treatment protocol for post-traumatic stress disorder (PTSD).
The researchers are seeking up to 330 military veterans with combat-related PTSD for the study, which will include both repetitive transcranial magnetic stimulation (rTMS) and cognitive processing therapy (CPT). The funding comes four months after publication of the team’s Journal of Affective Disorders study, which indicated that CPT for PTSD is more effective when paired with rTMS.

Affiliations

Medical students supervised
1997-99 W. Leo Sugrue
Residents supervised for senior research tutorial
1996-97 Ellen Deibert, M.D. 1998-99 Lauren Moo, M.D., Isaac Silverman, M.D.
Fellows Trained
1999-2001 Lauren Moo, M.D. 1999-2001 Scott Slotnick, Ph.D. 2004-2005 Juan Li, Ph.D. 2006 Richard King, M.D., Ph.D. 2006- Jacque Gamino, Ph.D. 2007-Gail Tillman, Ph.D. 2008-Raksha Anand, Ph.D. 2008-Elizabeth Kanter Bartz, Ph.D. Graduate student supervisors 2006-2008 Raksha Anand 2006-2007 Peter Fauver 2007-2009 Khamid Bhadikirov 2009-2010 Leonardo Estevez 2009- H-S Chiang 2010- Jeremy Strain 2010- Neena Rao
Undergraduate degree students supervised
1999-2000 Felix Yu 1997-99 Tifiini Smith 1996 Lauren Roginski 2006-10 Matthew Brier 2009-10 Shehznan Baqui 2009-10 Nistha Jajal 2009-10 Michael Lugo 2008-10 Rajen Patel